Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 10, 2012 - Issue 10
Submit an article Journal homepage
378
Views
16
CrossRef citations to date
0
Altmetric
Review

Prevention of influenza in healthy children

Bruce Y Lee Public Health Computational and Operations Research (PHICOR), University of Pittsburgh School of Medicine and Graduate School of Public Health, Pittsburgh, PA, USA. [email protected]
&
Mirat Shah Public Health Computational and Operations Research (PHICOR), University of Pittsburgh School of Medicine and Graduate School of Public Health, Pittsburgh, PA, USA; Public Health Computational and Operations Research (PHICOR), University of Pittsburgh School of Medicine and Graduate School of Public Health, Pittsburgh, PA, USA
Pages 1139-1152 | Published online: 10 Jan 2014

References

  • Brown ST, Tai JH, Bailey RR et al. Would school closure for the 2009 H1N1 influenza epidemic have been worth the cost?: a computational simulation of Pennsylvania. BMC Public Health 11, 353 (2011).
  • Iskander M, Booy R, Lambert S. The burden of influenza in children. Curr. Opin. Infect. Dis. 20(3), 259–263 (2007).
  • Fairbrother G, Cassedy A, Ortega-Sanchez IR et al.; New Vaccine Surveillance Network (NVSN). High costs of influenza: Direct medical costs of influenza disease in young children. Vaccine 28(31), 4913–4919 (2010).
  • Principi N, Esposito S. Are we ready for universal influenza vaccination in paediatrics? Lancet Infect. Dis. 4(2), 75–83 (2004).
  • Fiore AE, Uyeki TM, Broder K et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59(RR-8), 1–62 (2010).
  • Stevenson E, Barrios L, Cordell R et al. Pandemic influenza planning: addressing the needs of children. Am. J. Public Health 99(Suppl. 2), S255–S260 (2009).
  • Bell DM; World Health Organization Writing Group. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerging Infect. Dis. 12(1), 81–87 (2006).
  • Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 30(11), 1993–1998 (2012).
  • Della Cioppa G, Vesikari T, Sokal E, Lindert K, Nicolay U. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. Vaccine 29(47), 8696–8704 (2011).
  • Principi N, Esposito S, Marchisio P. Present and future of influenza prevention in pediatrics. Expert Opin. Biol. Ther. 11(5), 641–653 (2011).
  • Lee BY, Stalter RM, Bacon KM et al. Cost–effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patients. Am. J. Kidney Dis. 57(5), 724–732 (2011).
  • Lee BY, Ercius AK, Smith KJ. A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population. Vaccine 27(16), 2251–2257 (2009).
  • Jefferson T, Rivetti A, Harnden A, Di PC, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2, CD004879 (2008).
  • Waddington CS, Walker WT, Oeser C et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 340, c2649 (2010).
  • Vesikari T, Pellegrini M, Karvonen A et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr. Infect. Dis. J. 28(7), 563–571 (2009).
  • Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi. Viruses 5(2), 67–75 (2011).
  • Pedroza A, Huerta JG, Garcia Mde L et al. The safety and immunogenicity of influenza vaccine in children with asthma in Mexico. Int. J. Infect. Dis. 13(4), 469–475 (2009).
  • Sullender W, Fowler K, Krishnan A et al. Design and initiation of a study to assess the direct and indirect effects of influenza vaccine given to children in rural India. Vaccine 30(35), 5235–5239 (2012).
  • Verma R, Khanna P. Hepatitis A vaccine should receive priority in National Immunization Schedule in India. Hum. Vaccin. Immunother. 8(8), (2012).
  • Assi TM, Brown ST, Djibo A et al. Impact of changing the measles vaccine vial size on Niger’s vaccine supply chain: a computational model. BMC Public Health 11, 425 (2011).
  • Lee BY, Assi TM, Rajgopal J et al. Impact of introducing the pneumococcal and rotavirus vaccines into the routine immunization program in Niger. Am. J. Public Health 102(2), 269–276 (2012).
  • Hambidge SJ, Glanz JM, France EK et al.; Vaccine Safety Datalink Team. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA 296(16), 1990–1997 (2006).
  • France EK, Glanz JM, Xu S et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch. Pediatr. Adolesc. Med. 158(11), 1031–1036 (2004).
  • Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7(3), e33536 (2012).
  • Han F, Lin L, Warby SC et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann. Neurol. 70(3), 410–417 (2011).
  • Armstrong PK, Dowse GK, Effler PV et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 1(1), e000016 (2011).
  • The American Lung Association Asthma Clinical Research Centers. The safety of inactivated influenza vaccine in adults and children with asthma. N. Engl. J. Med. 345(21),1529–1536 (2001).
  • Jefferson T, Rivetti A, Harnden A, Di PC, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2, CD004879 (2008).
  • Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A. Safety of influenza vaccines in children. Lancet 366(9488), 803–804 (2005).
  • Lee BY, Biggerstaff BJ. Screening the United States blood supply for West Nile Virus: a question of blood, dollars, and sense. PLoS Med. 3(2), e99 (2006).
  • Chin RF, Neville BG, Peckham C, Wade A, Bedford H, Scott RC; NLSTEPSS Collaborative Group. Socioeconomic deprivation independent of ethnicity increases status epilepticus risk. Epilepsia 50(5), 1022–1029 (2009).
  • Lee BY, Tai JH, Bailey RR, Smith KJ, Nowalk AJ. Economics of influenza vaccine administration timing for children. Am. J. Manag. Care 16(3), e75–e85 (2010).
  • Fleming DM, Elliot AJ. Health benefits, risks, and cost–effectiveness of influenza vaccination in children. Pediatr. Infect. Dis. J. 27(Suppl. 11), S154–S158 (2008).
  • Luce BR, Nichol KL, Belshe RB et al. Cost–effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States. Vaccine 26(23), 2841–2848 (2008).
  • Lee BY, Tai JH, Bailey RR, Smith KJ, Nowalk AJ. Economics of influenza vaccine administration timing for children. Am J Manag Care 16(3),e75–e85 (2010).
  • Bhatt P, Block SL, Toback SL, Ambrose CS. Timing of the availability and administration of influenza vaccine through the vaccines for children program. Pediatr. Infect. Dis. J. 30(2), 100–106 (2011).
  • Nichol KL. Cost–effectiveness and socio-economic aspects of childhood influenza vaccination. Vaccine 29(43), 7554–7558 (2011).
  • Weycker D, Edelsberg J, Halloran ME et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine 23(10), 1284–1293 (2005).
  • Prosser LA, Bridges CB, Uyeki TM et al. Health benefits, risks, and cost–effectiveness of influenza vaccination of children. Emerging Infect. Dis. 12(10), 1548–1558 (2006).
  • Lee BY, Tai JH, McGlone SM et al. The potential economic value of a ‘universal’ (multi-year) influenza vaccine. Influenza Other Respi. Viruses 6(3), 167–175 (2012).
  • Centers for Disease Control and Prevention (CDC). Interim results: state-specific influenza vaccination coverage – United States, August 2010–February 2011. MMWR Morb. Mortal. Wkly Rep. 60(22),737–743 (2011).
  • Diekema DS. Improving childhood vaccination rates. N. Engl. J. Med. 366(5), 391–393 (2012).
  • Centers for Disease Control and Prevention (CDC). Intent to receive influenza A (H1N1) 2009 monovalent and seasonal influenza vaccines – two counties, North Carolina, August 2009. MMWR Morb Mortal Wkly Rep. 58(50),1401–1405 (2009).
  • Falagas ME, Zarkadoulia E. Factors associated with suboptimal compliance to vaccinations in children in developed countries: a systematic review. Curr. Med. Res. Opin. 24(6), 1719–1741 (2008).
  • Cawley J, Hull HF, Rousculp MD. Strategies for implementing school-located influenza vaccination of children: a systematic literature review. J. Sch. Health 80(4), 167–175 (2010).
  • Tran CH, McElrath J, Hughes P et al. Implementing a community-supported school-based influenza immunization program. Biosecur. Bioterror. 8(4), 331–341 (2010).
  • Hull HF, Ambrose CS. The impact of school-located influenza vaccination programs on student absenteeism: a review of the U.S. literature. J. Sch. Nurs. 27(1), 34–42 (2011).
  • Martin E. Improving influenza vaccination rates for pediatric asthmatics by use of an asthma educational tool and a patient electronic care system. Clin. Pediatr. (Phila.) 47(6), 588–592 (2008).
  • Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM; Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza –recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recomm. Rep. 60(1), 1–24 (2011).
  • Wang K, Shun-Shin M, Gill P, Perera R, Harnden A. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst. Rev. 4, CD002744 (2012).
  • Hayden FG, Belshe R, Villanueva C et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J. Infect. Dis. 189(3), 440–449 (2004).
  • Welliver R, Monto AS, Carewicz O et al.; Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 285(6), 748–754 (2001).
  • Hayden FG, Gubareva LV, Monto AS et al.; Zanamivir Family Study Group. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N. Engl. J. Med. 343(18), 1282–1289 (2000).
  • Monto AS, Pichichero ME, Blanckenberg SJ et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J. Infect. Dis. 186(11), 1582–1588 (2002).
  • Goldstein E, Cowling BJ, O’Hagan JJ et al. Oseltamivir for treatment and prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009. BMC Infect. Dis. 10, 211 (2010).
  • Lee DH, Kim CW, Kim JH et al. Risk factors for laboratory-confirmed household transmission of pandemic H1N1 2009 infection. Am. J. Infect. Control 38(10), e43–e45 (2010).
  • Komiya N, Gu Y, Kamiya H et al. Household transmission of pandemic 2009 influenza A (H1N1) virus in Osaka, Japan in May 2009. J. Infect. 61(4), 284–288 (2010).
  • Leung YH, Li MP, Chuang SK. A school outbreak of pandemic (H1N1) 2009 infection: assessment of secondary household transmission and the protective role of oseltamivir. Epidemiol. Infect. 139(1), 41–44 (2011).
  • Ng S, Cowling BJ, Fang VJ et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin. Infect. Dis. 50(5), 707–714 (2010).
  • Talbird SE, Brogan AJ, Winiarski AP. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1–12 years in the U.S. Am. J. Prev. Med. 37(5), 381–388 (2009).
  • Tamura D, Sugaya N, Ozawa M et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin. Infect. Dis. 52(4), 432–437 (2011).
  • Rajatonirina S, Heraud JM, Randrianasolo L et al. Pandemic influenza A(H1N1) 2009 virus outbreak among boarding school pupils in Madagascar: compliance and adverse effects of prophylactic oseltamivir treatment. J. Infect. Dev. Ctries. 5(3), 156–162 (2011).
  • Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1) May 2009 – an internet-based cross-sectional survey. Euro Surveill. 14(30), 19287 (2009).
  • Wallensten A, Oliver I, Lewis D, Harrison S. Compliance and side effects of prophylactic oseltamivir treatment in a school in South West England. Euro Surveill. 14(30), 19285 (2009).
  • Lee BY, McGlone SM, Bailey RR et al. To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling. PLoS ONE 5(6), e11284 (2010).
  • Cannell JJ, Vieth R, Umhau JC et al. Epidemic influenza and vitamin D. Epidemiol. Infect. 134(6), 1129–1140 (2006).
  • Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J. Clin. Virol. 50(3), 194–200 (2011).
  • Guo R, Pittler MH, Ernst E. Complementary medicine for treating or preventing influenza or influenza-like illness. Am. J. Med. 120(11), 923–929.e3 (2007).
  • Matsumoto K, Yamada H, Takuma N, Niino H, Sagesaka YM. Effects of green tea catechins and theanine on preventing influenza infection among healthcare workers: a randomized controlled trial. BMC Complement. Altern. Med. 11, 15 (2011).
  • Melchart D, Walther E, Linde K, Brandmaier R, Lersch C. Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial. Arch. Fam. Med. 7(6), 541–545 (1998).
  • Cohen HA, Varsano I, Kahan E, Sarrell EM, Uziel Y. Effectiveness of an herbal preparation containing echinacea, propolis, and vitamin C in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled, multicenter study. Arch. Pediatr. Adolesc. Med. 158(3), 217–221 (2004).
  • Linday LA, Shindledecker RD, Tapia-Mendoza J, Dolitsky JN. Effect of daily cod liver oil and a multivitamin-mineral supplement with selenium on upper respiratory tract pediatric visits by young, inner-city, Latino children: randomized pediatric sites. Ann. Otol. Rhinol. Laryngol. 113(11), 891–901 (2004).
  • Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am. J. Clin. Nutr. 91(5), 1255–1260 (2010).
  • Schmier JK, Rachman NJ, Halpern MT. The cost–effectiveness of omega-3 supplements for prevention of secondary coronary events. Manag. Care 15(4), 43–50 (2006).
  • Tice JA, Ross E, Coxson PG et al. Cost–effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA 286(8), 936–943 (2001).
  • Norman K, Pirlich M, Smoliner C et al. Cost–effectiveness of a 3-month intervention with oral nutritional supplements in disease-related malnutrition: a randomised controlled pilot study. Eur. J. Clin. Nutr. 65(6), 735–742 (2011).
  • Jansen JP, Gaugris S, Bergman G, Sen SS. Cost–effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands. Curr. Med. Res. Opin. 24(3), 671–684 (2008).
  • Casey GJ, Sartori D, Horton SE et al. Weekly iron–folic acid supplementation with regular deworming is cost–effective in preventing anaemia in women of reproductive age in Vietnam. PLoS ONE 6(9), e23723 (2011).
  • Wu JT, Cowling BJ, Lau EH et al. School closure and mitigation of pandemic (H1N1) 2009, Hong Kong. Emerging Infect. Dis. 16(3), 538–541 (2010).
  • Wheeler CC, Erhart LM, Jehn ML. Effect of school closure on the incidence of influenza among school-age children in Arizona. Public Health Rep. 125(6), 851–859 (2010).
  • Chowell G, Echevarría-Zuno S, Viboud C et al. Characterizing the epidemiology of the 2009 influenza A/H1N1 pandemic in Mexico. PLoS Med. 8(5), e1000436 (2011).
  • Cowling BJ, Lau EH, Lam CL et al. Effects of school closures, 2008 winter influenza season, Hong Kong. Emerging Infect. Dis. 14(10), 1660–1662 (2008).
  • Cauchemez S, Bhattarai A, Marchbanks TL et al.; Pennsylvania H1N1 working group. Role of social networks in shaping disease transmission during a community outbreak of 2009 H1N1 pandemic influenza. Proc. Natl Acad. Sci. USA 108(7), 2825–2830 (2011).
  • Glass K, Barnes B. How much would closing schools reduce transmission during an influenza pandemic? Epidemiology 18(5), 623–628 (2007).
  • Sasaki A, Hoen AG, Ozonoff A et al. Evidence-based tool for triggering school closures during influenza outbreaks, Japan. Emerging Infect. Dis. 15(11), 1841–1843 (2009).
  • Lee BY, Brown ST, Cooley P et al. Simulating school closure strategies to mitigate an influenza epidemic. J. Public Health Manag. Pract. 16(3), 252–261 (2010).
  • Halloran ME, Ferguson NM, Eubank S et al. Modeling targeted layered containment of an influenza pandemic in the United States. Proc. Natl Acad. Sci. USA 105(12), 4639–4644 (2008).
  • Cauchemez S, Ferguson NM, Wachtel C et al. Closure of schools during an influenza pandemic. Lancet Infect. Dis. 9(8), 473–481 (2009).
  • Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 442(7101), 448–452 (2006).
  • Jefferson T, Del Mar C, Dooley L et al. Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review. BMJ 339, b3675 (2009).
  • Pang X, Yang P, Li S et al. Pandemic (H1N1) 2009 among quarantined close contacts, Beijing, People’s Republic of China. Emerging Infect. Dis. 17(10), 1824–1830 (2011).
  • van Gemert C, Hellard M, McBryde ES et al. Intrahousehold transmission of pandemic (H1N1) 2009 virus, Victoria, Australia. Emerging Infect. Dis. 17(9), 1599–1607 (2011).
  • Jefferson T, Del Mar CB, Dooley L et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst. Rev. 7, CD006207 (2011).
  • Halder N, Kelso JK, Milne GJ. Analysis of the effectiveness of interventions used during the 2009 A/H1N1 influenza pandemic. BMC Public Health 10, 168 (2010).
  • Effler PV, Carcione D, Giele C, Dowse GK, Goggin L, Mak DB. Household responses to pandemic (H1N1) 2009-related school closures, Perth, Western Australia. Emerging Infect. Dis. 16(2), 205–211 (2010).
  • Halloran ME, Longini IM, Cowart DM, Nizam A. Community interventions and the epidemic prevention potential. Vaccine 20(27-28), 3254–3262 (2002).
  • Kelso JK, Milne GJ, Kelly H. Simulation suggests that rapid activation of social distancing can arrest epidemic development due to a novel strain of influenza. BMC Public Health 9, 117 (2009).
  • Longini IM Jr, Nizam A, Xu S et al. Containing pandemic influenza at the source. Science 309(5737), 1083–1087 (2005).
  • Lempel H, Epstein JM, Hammond RA. Economic cost and health care workforce effects of school closures in the US. PLoS Curr. 1, RRN1051 (2009).
  • Berkman BE. Mitigating pandemic influenza: the ethics of implementing a school closure policy. J. Public Health Manag. Pract. 14(4), 372–378 (2008).
  • Impact of seasonal influenza-related school closures on families – southeastern Kentucky, February 2008. MMWR Morb. Mortal. Wkly Rep. 58(50), 1405–1409 (2009).
  • Johnson AJ, Moore ZS, Edelson PJ et al. Household responses to school closure resulting from outbreak of influenza B, North Carolina. Emerging Infect. Dis. 14(7), 1024–1030 (2008).
  • Canini L, Andréoletti L, Ferrari P et al. Surgical mask to prevent influenza transmission in households: a cluster randomized trial. PLoS ONE 5(11), e13998 (2010).
  • Stebbins S, Stark JH, Vukotich CJ Jr. Compliance with a multilayered nonpharmaceutical intervention in an urban elementary school setting. J. Public Health Manag. Pract. 16(4), 316–324 (2010).
  • Guinan M, McGuckin M, Ali Y. The effect of a comprehensive handwashing program on absenteeism in elementary schools. Am. J. Infect. Control 30(4), 217–220 (2002).
  • Brienen NC, Timen A, Wallinga J, van Steenbergen JE, Teunis PF. The effect of mask use on the spread of influenza during a pandemic. Risk Anal. 30(8), 1210–1218 (2010).
  • Talaat M, Afifi S, Dueger E et al. Effects of hand hygiene campaigns on incidence of laboratory-confirmed influenza and absenteeism in schoolchildren, Cairo, Egypt. Emerging Infect. Dis. 17(4), 619–625 (2011).
  • MacIntyre CR, Cauchemez S, Dwyer DE et al. Face mask use and control of respiratory virus transmission in households. Emerging Infect. Dis. 15(2), 233–241 (2009).
  • Cowling BJ, Fung RO, Cheng CK et al. Preliminary findings of a randomized trial of non-pharmaceutical interventions to prevent influenza transmission in households. PLoS ONE 3(5), e2101 (2008).
  • Cowling BJ, Chan KH, Fang VJ et al. Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial. Ann. Intern. Med. 151(7), 437–446 (2009).
  • Larson EL, Ferng YH, Wong-McLoughlin J, Wang S, Haber M, Morse SS. Impact of non-pharmaceutical interventions on URIs and influenza in crowded, urban households. Public Health Rep. 125(2), 178–191 (2010).
  • Lee BY, Bailey RR, Smith KJ et al. Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis. Infect. Control Hosp. Epidemiol. 31(6), 598–606 (2010).
  • Lee BY, Wettstein ZS, McGlone SM et al. Economic value of norovirus outbreak control measures in healthcare settings. Clin. Microbiol. Infect. 17(4), 640–646 (2011).
  • Lee BY, McGlone SM, Doi Y, Bailey RR, Harrison LH. Economic value of Acinetobacter baumannii screening in the intensive care unit (ICU). Clin Microbiol Infect. 17(11),1691–1697 (2011).
  • Karchmer TB, Durbin LJ, Simonton BM, Farr BM. Cost–effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. 51(2), 126–132 (2002).
  • Lee BY, Burke DS. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine 28(16), 2806–2809 (2010).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.